‘Unconscionable’: FDA Approves New COVID Vaccines — Even for Infants as Young as 6 Months — Based on Minimal Data or Testing
The U.S. Food and Drug Administration said the new vaccines are “formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death.” However, the vaccines target the XBB.1.5 variant, which “is declining in the U.S.,” according to CNBC.
The U.S. Food and Drug Administration (FDA) on Monday approved updated mRNA COVID-19 vaccines produced by Pfizer-BioNTech and Moderna, paving the way for their approval by the Centers for Disease Control and Prevention (CDC).
The CDC’s Advisory Committee on Immunization Practices (ACIP) is meeting today to vote on whether to recommend the two vaccines, CNBC reported. Following ACIP’s vote, CDC Director Mandy Cohen is “likely” to approve its recommendation, Endpoints News reported, opening the door for the vaccines’ public availability.
The vaccines received FDA approval for people ages 12 and up, and Emergency Use Authorization (EUA) for children from 6 months to 11 years. Ages 5 and over will be eligible to receive a single dose, previously vaccinated children between 6 months and 4 years of age will receive one or two doses, while unvaccinated children in the same age group will be eligible for two Moderna doses or three Pfizer-BioNTech doses.
According to the FDA, the new vaccines are “formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death.”
However, the vaccines target the XBB.1.5 variant, which “is declining in the U.S.,” according to CNBC, citing CDC data…
READ MORE HERE FROM SOURCE >> https://childrenshealthdefense.org/defender/fda-approves-new-covid-vaccines-infants-minimal-data-testing/